Millions of people suffer from acid reflux. This seemingly harmless symptom can lead to gastroesophageal reflux disease (GERD) or Barrett’s esophagus (BE). BE is the primary risk factor for a type of cancer called esophageal adenocarcinoma,1-3 which makes early detection and treatment essential.

Get the information you need to take charge of your care. Submit the form on the right to receive helpful periodic email updates with:

  • Treatment information
  • Personal stories and patient videos
  • Risk assessment tools
  • Doctor discussion guides
  • Answers to frequently asked questions

Additional Resources to Help You Take the Next Steps:

By checking this box you verify that you have read and agree to these Legal Statements and Privacy Policy. In addition you agree to permit Medtronic to send you materials on its products and services that may interest you. Also, Medtronic may contact you from time to time to collect additional information and inform you about special offers and updates on the Barrx™ RF ablation system or other Barrett's esophagus related health matters. Moreover, you authorize Medtronic to use the personal information you have provided on this form for the purposes stated herein.

If you ever wish to stop receiving email updates, you can unsubscribe at any time.

References: 1. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59(8):1030-6. 2. Pohl H, Welch G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142-6. 3.Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut. 2012 Jul;61(7):970-6.